Guan et al. functionalized liposomes with a tumor-homing and -penetrating peptide, iRGD, as a carrier of an ASO against androgen receptor (AR) for prostate cancer treatment, and these iRGD-liposomes markedly improved the ASO efficacy in suppressing the growth of tumor [72]. Here, AR is linked to neoplasm.